XML 60 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Debt Obligations - 2027 Term Loan - Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended
Jan. 07, 2019
USD ($)
Mar. 31, 2022
USD ($)
Jan. 31, 2022
USD ($)
item
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Sep. 14, 2022
USD ($)
Jan. 05, 2022
USD ($)
tranche
Apr. 30, 2020
USD ($)
Feb. 29, 2016
USD ($)
Debt Instrument [Line Items]                  
Outstanding amount paid off         $ 81,750        
Outstanding amount payoff         109,000        
2027 Term Loans                  
Debt Instrument [Line Items]                  
Debt Instrument, Interest Rate During Period       13.03%          
2027 Term Loans | BioPharma Credit Investments V GP LLC                  
Debt Instrument [Line Items]                  
Principal amount             $ 300,000    
Number of tranches | tranche             4    
Net carrying value       $ 245,718          
Quarterly payments | item     5            
Loan agreement covenants, minimum trailing twelve month net sales for current quarter     $ 200,000 200,000          
Loan agreement covenants, minimum trailing twelve month net sales for the quarter ended March 30, 2024     210,000            
Loan agreement covenants, minimum trailing twelve-month net sales for the quarter ended June 30, 2024     230,000            
Loan agreement covenants, minimum trailing twelve-month net sales for the quarter ended September 30, 2024     270,000            
Loan agreement covenants, minimum trailing twelve-month net sales for the quarter ended December 31, 2024 and thereafter     $ 300,000            
Mandatory prepayment term     10 days            
Debt discounts and issuance costs     $ 6,800            
Remaining unamortized debt discount and debt offering costs       $ 4,282          
2027 Term Loans | Additional facility amount | BioPharma Credit Investments V GP LLC                  
Debt Instrument [Line Items]                  
Principal amount     $ 100,000            
2027 Term Loans | Through March 31, 2023 | BioPharma Credit Investments V GP LLC                  
Debt Instrument [Line Items]                  
Stated interest rate     8.25%            
2027 Term Loans | Through March 31, 2023 | BioPharma Credit Investments V GP LLC | Three-month LIBOR                  
Debt Instrument [Line Items]                  
Floor On Variable Rate     1.00%            
2027 Term Loans | Starting April 1, 2023 | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]                  
Debt Instrument [Line Items]                  
Amount added to the variable component       0.26161%          
Floor On Variable Rate       1.00%          
2027 Term Loans | Starting April 1, 2023 | BioPharma Credit Investments V GP LLC                  
Debt Instrument [Line Items]                  
Stated interest rate       8.25%          
Tranche A Loan, funded January 5, 2022 | BioPharma Credit Investments V GP LLC                  
Debt Instrument [Line Items]                  
Principal amount             $ 100,000    
Debt discounts and issuance costs     $ 7,800            
Tranche B Loan, funded on March 31, 2022 | BioPharma Credit Investments V GP LLC                  
Debt Instrument [Line Items]                  
Principal amount   $ 100,000     100,000        
Debt discounts and issuance costs         2,300        
Convertible notes, Issuance Cost   $ 1,000     $ 1,000        
Tranche C Loan, not funded between April 1, 2022 and March 17, 2023 | BioPharma Credit Investments V GP LLC                  
Debt Instrument [Line Items]                  
Principal amount     50,000            
Tranche D Loan, funded on September 14, 2022 | BioPharma Credit Investments V GP LLC                  
Debt Instrument [Line Items]                  
Principal amount           $ 50,000      
Convertible notes, Issuance Cost           $ 500      
1.5% Convertible Senior Subordinated Notes due 2026 | Convertible Notes                  
Debt Instrument [Line Items]                  
Principal amount               $ 230,000  
Net carrying value       $ 225,900          
Stated interest rate               1.50%  
Remaining unamortized debt discount and debt offering costs       $ 4,100          
Effective interest rate       2.10%          
1.5% Convertible Senior Subordinated Notes due 2026 | BioPharma Credit Investments V GP LLC | Scenario, Plan | Minimum                  
Debt Instrument [Line Items]                  
Principal amount     50,000            
8.2% Convertible Notes due 2022 | Convertible Notes                  
Debt Instrument [Line Items]                  
Principal amount     100,000           $ 100,000
Stated interest rate   8.20%     8.20%       8.20%
Outstanding amount payoff   $ 111,100 111,100            
2025 Term Loan | Lender                  
Debt Instrument [Line Items]                  
Principal amount $ 75,000   75,000            
Outstanding amount paid off     $ 81,900            
Total term of the loan 6 years                
Tranches A, B and D | BioPharma Credit Investments V GP LLC                  
Debt Instrument [Line Items]                  
Remaining unamortized debt discount and debt offering costs       $ 4,300          
Remaining term       3 years 9 months 18 days